Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

News, weather, traffic and more from FOX 5, serving the District of Columbia, Maryland and Virginia. Super Bowl commercials ...

The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis conducted by Future Market Insights. In 2022, the market was valued at USD 777.4 ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Hypoparathyroidism. ORLANDO, FLORIDA / ACCESSWIRE / February 3, 2025 / The Assistance F ...

Hormone Replacement Therapy MarketThe global hormone replacement therapy (HRT) market is poised for steady growth, with a projected compound annual growth rate (CAGR) of 3.5%. From an estimated market ...

Ascendis Pharma boasts several commercial stage products. Read why ASND stock is an interesting speculative investment opportunity.

The presentation scheduled for Tuesday, February 11th at 12:40-1:10 PM ET in Track 1 will feature a business overview and update by Miranda Toledano, the Company’s Chief Executive Officer.

Hypoparathyroidism (hypoPT) is an uncommon condition that happens when your body doesn’t make enough parathyroid hormone (PTH) or the blood levels of PTH are undetectable. How Do You Know If ...

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after ...